-+ 0.00%
-+ 0.00%
-+ 0.00%

Goldman Sachs Maintains Neutral on Ultragenyx Pharmaceutical, Lowers Price Target to $17

Benzinga·11/04/2026 17:44:59
Listen to the news
Goldman Sachs analyst Salveen Richter maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Neutral and lowers the price target from $19 to $17.